They then studied DLBCL patients (n = 157) treated with R-CHOP by including GOT2 expression in a Cox proportional risk model and found high GOT2 expression (HR 2.28, P = 0.03756) was significantly associated with shorter OS in DLBCL patients and could be used as a marker of poor prognosis in DLBCL 60. The gene discussed is GOT2; the disease is diffuse large B-cell lymphoma.